Compare C-RAD AB with Similar Stocks
Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 29.86
2
Healthy long term growth as Net Sales has grown by an annual rate of 14.81% and Operating profit at 26.25%
3
Positive results in Mar 26
4
With ROE of 3.00%, it has a fair valuation with a 2.51 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,064 Million (Small Cap)
84.00
NA
0.00%
-0.49
3.00%
3.06
Revenue and Profits:
Net Sales:
105 Million
(Quarterly Results - Mar 2026)
Net Profit:
11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
49.81%
0%
49.81%
6 Months
21.82%
0%
21.82%
1 Year
11.02%
0%
11.02%
2 Years
-8.6%
0%
-8.6%
3 Years
38.08%
0%
38.08%
4 Years
-5.71%
0%
-5.71%
5 Years
-23.32%
0%
-23.32%
C-RAD AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.81%
EBIT Growth (5y)
26.25%
EBIT to Interest (avg)
29.86
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.49
Sales to Capital Employed (avg)
1.46
Tax Ratio
39.10%
Dividend Payout Ratio
32.29%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
32.53%
ROE (avg)
10.39%
Valuation key factors
Factor
Value
P/E Ratio
84
Industry P/E
Price to Book Value
2.51
EV to EBIT
11.64
EV to EBITDA
9.94
EV to Capital Employed
3.99
EV to Sales
1.59
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
34.26%
ROE (Latest)
3.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
104.70
118.80
-11.87%
Operating Profit (PBDIT) excl Other Income
11.50
23.90
-51.88%
Interest
0.00
17.70
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
11.20
-8.10
238.27%
Operating Profit Margin (Excl OI)
78.30%
178.50%
-10.02%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is -11.87% vs 0.68% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 238.27% vs -150.62% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
441.90
469.00
-5.78%
Operating Profit (PBDIT) excl Other Income
65.30
74.10
-11.88%
Interest
0.90
0.30
200.00%
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
10.50
56.40
-81.38%
Operating Profit Margin (Excl OI)
135.80%
149.80%
-1.40%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -5.78% vs 10.46% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -81.38% vs 58.87% in Dec 2024
About C-RAD AB 
C-RAD AB
Pharmaceuticals & Biotechnology
C-Rad AB is a Sweden-based holding company active in the medical equipment industry. It offers products and solutions to the radiation therapy market. C-Rad AB is the parent company within the C-Rad group (the Group). The Group provides such products, as Sentinel, a surface contour laser scanning system for patient positioning, monitoring and gating applications; Catalyst, a surface scanning system, which allows the identification and tracking of markers, and GEMini, a system based on a gaseous detector using metal converters interleaved with Gas Electron Multipliers (GEMs), as well as other products. The Company operates through several subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB, C-RAD Innovation AB and Cyrpa International Sprl. The Company’s largest shareholder is Inter Life Science AB.
Company Coordinates 
Company Details
Bredgrand 18 , UPPSALA None : 753 20
Registrar Details






